MIM
AVXL icon

MetLife Investment Management’s Anavex Life Sciences AVXL Stock Holding History

MetLife Investment Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Buy
51,627
+16,197
+46% +$47.9K ﹤0.01% 2637
2026
Q1 		$109K Sell
35,430
-290
-0.8% -$1.26K ﹤0.01% 2500
2025
Q4 		$127K Sell
35,720
-8,885
-20% -$54.4K ﹤0.01% 2488
2025
Q3 		$397K Buy
+44,605
New +$452K ﹤0.01% 1920
2025
Q2 		– Sell
-45,343
Closed -$389K – 2815
2025
Q1 		$389K Sell
45,343
-834
-2% -$7.88K ﹤0.01% 1846
2024
Q4 		$496K Buy
46,177
+5,816
+14% +$44.7K ﹤0.01% 1803
2024
Q3 		$229K Hold
40,361
– – ﹤0.01% 2217
2024
Q2 		$170K Buy
40,361
+12,095
+43% +$48.9K ﹤0.01% 2347
2024
Q1 		$144K Sell
28,266
-7,983
-22% -$44.9K ﹤0.01% 2364
2023
Q4 		$337K Hold
36,249
– – ﹤0.01% 1922
2023
Q3 		$237K Hold
36,249
– – ﹤0.01% 2107
2023
Q2 		$295K Hold
36,249
– – ﹤0.01% 2025
2023
Q1 		$311K Hold
36,249
– – ﹤0.01% 1935
2022
Q4 		$336K Hold
36,249
– – ﹤0.01% 1895
2022
Q3 		$374K Buy
36,249
+2,553
+8% +$26.9K ﹤0.01% 1847
2022
Q2 		$337K Sell
33,696
-3,219
-9% -$30.5K ﹤0.01% 1942
2022
Q1 		$454K Buy
36,915
+13,623
+58% +$168K ﹤0.01% 1833
2021
Q4 		$404K Hold
23,292
– – ﹤0.01% 1626
2021
Q3 		$418K Hold
23,292
– – ﹤0.01% 1630
2021
Q2 		$532K Hold
23,292
– – ﹤0.01% 1534
2021
Q1 		$348K Buy
23,292
+15,192
+188% +$166K ﹤0.01% 1731
2020
Q4 		$43.7K Buy
8,100
+3,381
+72% +$17.8K ﹤0.01% 2256
2020
Q3 		$21.5K Sell
4,719
-21,037
-82% -$90.5K ﹤0.01% 2283
2020
Q2 		$127K Buy
+25,756
New +$97.3K ﹤0.01% 2145

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MetLife Investment Management's AVXL Position: Q2 2026 in Review

MetLife Investment Management increased its Anavex Life Sciences (AVXL) stake by 46% in Q2 2026, buying an estimated $47.9K and bringing the position to 51,627 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #2637.

MetLife Investment Management first reported a position in AVXL in Q2 2020 and has held it in 24 quarters since. The position peaked at $532K in Q2 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • MetLife Investment Management held 51,627 shares of Anavex Life Sciences worth $134K as of Q2 2026.
  • MetLife Investment Management bought 16,197 Anavex Life Sciences shares in Q2 2026, an estimated $47.9K.
  • Anavex Life Sciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2637 holding.
  • MetLife Investment Management first reported a position in Anavex Life Sciences in Q2 2020 and has held it in 24 quarters since.
  • MetLife Investment Management's Anavex Life Sciences position peaked at $532K in Q2 2021.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.